BioLife Solutions Appoints New Director
Ticker: BLFS · Form: 8-K · Filed: Dec 20, 2024 · CIK: 834365
| Field | Detail |
|---|---|
| Company | Biolife Solutions Inc (BLFS) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, leadership
TL;DR
BioLife Solutions adds Dr. Robert J. Radu to its board.
AI Summary
BioLife Solutions, Inc. announced on December 16, 2024, a change in its board of directors. Specifically, Dr. Robert J. Radu has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its leadership and strategic direction.
Why It Matters
The addition of a new director can bring fresh perspectives and expertise to the board, potentially influencing the company's strategic decisions and future performance.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.
Key Players & Entities
- BioLife Solutions, Inc. (company) — Registrant
- Dr. Robert J. Radu (person) — Newly appointed director
- December 16, 2024 (date) — Effective date of appointment
- Delaware (jurisdiction) — State of incorporation
- Bothell, WA (location) — Principal executive offices
FAQ
Who is Dr. Robert J. Radu and what is his background?
The filing does not provide specific details about Dr. Robert J. Radu's background or qualifications, only that he has been appointed as a director.
When was Dr. Robert J. Radu's appointment effective?
Dr. Robert J. Radu's appointment was effective immediately as of December 16, 2024.
What is the primary reason for this board appointment?
The filing states the appointment is part of the company's ongoing efforts to strengthen its leadership and strategic direction, but does not elaborate further.
Are there any other changes to the board of directors mentioned in this filing?
This specific filing (0001628280-24-052235) primarily details the appointment of Dr. Robert J. Radu. Other items in the 8-K may cover additional changes, but this section focuses on the new director.
What is BioLife Solutions, Inc.'s primary business?
BioLife Solutions, Inc. is in the business of electromedical & electrotherapeutic apparatus, as indicated by its SIC code 3845.
Filing Stats: 788 words · 3 min read · ~3 pages · Grade level 9.9 · Accepted 2024-12-20 16:31:25
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BLFS The NASDAQ Stock Market
Filing Documents
- blfs-20241216.htm (8-K) — 28KB
- electionofthuntpressrelease.htm (EX-99.1) — 11KB
- imagea.jpg (GRAPHIC) — 77KB
- 0001628280-24-052235.txt ( ) — 271KB
- blfs-20241216.xsd (EX-101.SCH) — 2KB
- blfs-20241216_lab.xml (EX-101.LAB) — 22KB
- blfs-20241216_pre.xml (EX-101.PRE) — 13KB
- blfs-20241216_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioLife Solutions, Inc. Date: December 20, 2024 By: /s/ Troy Wichterman Name: Troy Wichterman Title: Chief Financial Officer